Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers. Idelalisib acts as a phosphoinositide 3-kinase inhibitor;...
16 KB (1,254 words) - 06:35, 1 July 2024
4-quinazolinone core with a 2-substituted phenyl group at nitrogen atom 3. Idelalisib (Zydelig) Cloroqualone SL-164 (Dicloqualone) Diproqualone Etaqualone Mebroqualone...
2 KB (159 words) - 20:23, 25 January 2024
potential for combination is expected from other drugs such as ibrutinib and idelalisib, both of which were also approved in 2014 to treat CLL.: 7–8 Venetoclax...
27 KB (2,564 words) - 02:20, 16 July 2024
the first one to be approved for treatment in clinical practice was idelalisib in 2014. Several others followed, and even more are still under development...
45 KB (5,359 words) - 22:07, 19 July 2024
Panobinostat Romidepsin Vorinostat) PIKI (Pi3K) (Alpelisib Copanlisib Duvelisib Idelalisib Umbralisib‡) Receptor antagonists ERA (Atrasentan) Retinoid X receptor...
31 KB (2,906 words) - 07:45, 19 August 2024
Panobinostat Romidepsin Vorinostat) PIKI (Pi3K) (Alpelisib Copanlisib Duvelisib Idelalisib Umbralisib‡) Receptor antagonists ERA (Atrasentan) Retinoid X receptor...
36 KB (3,299 words) - 19:46, 10 August 2024
Pharmacologically Relevant Chiral Molecules: The Cases of Avibactam, Cephems, and Idelalisib as Benchmarks for Antibiotics and Anticancer Drugs". Symmetry. 13 (4):...
4 KB (383 words) - 16:26, 20 May 2024
Panobinostat Romidepsin Vorinostat) PIKI (Pi3K) (Alpelisib Copanlisib Duvelisib Idelalisib Umbralisib‡) Receptor antagonists ERA (Atrasentan) Retinoid X receptor...
61 KB (6,082 words) - 05:23, 17 June 2024
Panobinostat Romidepsin Vorinostat) PIKI (Pi3K) (Alpelisib Copanlisib Duvelisib Idelalisib Umbralisib‡) Receptor antagonists ERA (Atrasentan) Retinoid X receptor...
26 KB (2,420 words) - 15:49, 26 June 2024
Panobinostat Romidepsin Vorinostat) PIKI (Pi3K) (Alpelisib Copanlisib Duvelisib Idelalisib Umbralisib‡) Receptor antagonists ERA (Atrasentan) Retinoid X receptor...
4 KB (128 words) - 11:38, 22 April 2024